These findings overlap with findings from Wagner et al. in which PD-L1- expressing TAM were found across all analyzed breast cancer subtypes, suggesting that TAM have the ability to negatively influence the response to immunotherapy by checkpoint inhibition [50]. Here, CD274 is linked to breast cancer.